Fouad Namouni, Blueprint Medicines president of R&D (BMS)
Another Big Pharma 'lifer' in the top ranks of R&D is starting a new chapter in biotech
Fouad Namouni, a storied research exec who went from project leader on Opdivo and Yervoy to the top of the oncology research group at Bristol …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
